Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA-4783 plus paclitaxel vs paclitaxel alone in chemotherapy-naïve stage IV metastatic melanoma
2007-001421-10Phase 3Completed
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elesclomol in melanoma (2 arms), sponsored by Synta Pharmaceuticals Corp. Primary endpoint: Progression-free survival. Started Jun 2007; status: completed.
02
Drugs
elesclomol
03
Conditions
melanoma
Beyond the preview
Go deeper on 2007-001421-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001421-10.